Labcyte wins $1M award for protein biomarker research; Investigators outline Roche drug's impact on macular degeneration;

> The NCI has awarded Labcyte $1 million to work on new technology for evaluating protein biomarkers for cancer, beginning with a focus on breast cancer. Story (reg. req.)

> Investigators have been spelling out the effect of Roche's ($RHHBY) lampalizumab on a biomarker-defined subset of patients with macular degeneration. Report (reg. req.)

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Bayer strengthened its ties with Scottish AI developer Blackford Analysis to build a one-stop shop for applications in medical imaging.

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Boston Scientific has moved to hive off the specialty pharmaceuticals division it picked up through last year’s $4.2 billion acquisition of BTG.